Published in Mov Disord on January 01, 1991
Deep Brain Stimulation Therapy in Movement Disorders | NCT02119611
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol (2010) 2.64
Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression. Mov Disord (2011) 2.12
Pathophysiology of parkinsonism. Clin Neurophysiol (2008) 1.71
Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus. Exp Brain Res (2004) 1.51
Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord (2009) 1.30
Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord (2011) 1.18
Hemiballism: report of 25 cases. J Neurol Neurosurg Psychiatry (1994) 1.13
The history and future of deep brain stimulation. Neurotherapeutics (2008) 1.11
Subthalamic nucleus stimulation in Parkinson's disease : anatomical and electrophysiological localization of active contacts. J Neurol (2006) 1.10
Closing the loop of deep brain stimulation. Front Syst Neurosci (2013) 1.07
Deep brain stimulation for movement and other neurologic disorders. Ann N Y Acad Sci (2012) 1.01
Balancing the brain: resting state networks and deep brain stimulation. Front Integr Neurosci (2011) 1.00
Relative contributions of local cell and passing fiber activation and silencing to changes in thalamic fidelity during deep brain stimulation and lesioning: a computational modeling study. J Comput Neurosci (2011) 1.00
Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease. J Neurol (1999) 0.98
The treatment of movement disorders by deep brain stimulation. Neurotherapeutics (2008) 0.96
Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry (2001) 0.96
Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. Front Neuroanat (2015) 0.93
What happened to posteroventral pallidotomy for Parkinson's disease and dystonia? Neurotherapeutics (2008) 0.92
Persistent hemiballism in Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 0.92
Changing views of basal ganglia circuits and circuit disorders. Clin EEG Neurosci (2010) 0.91
Functional anatomy of movement disorders. J Anat (2000) 0.90
STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice. Mov Disord Clin Pract (2014) 0.90
Deep-Brain Stimulation for Basal Ganglia Disorders. Basal Ganglia (2011) 0.89
Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther (2011) 0.87
Neural plasticity in human brain connectivity: the effects of long term deep brain stimulation of the subthalamic nucleus in Parkinson's disease. PLoS One (2014) 0.87
Subthalamic nucleus long-range synchronization-an independent hallmark of human Parkinson's disease. Front Syst Neurosci (2013) 0.85
Bilateral high-frequency stimulation of the subthalamic nucleus on attentional performance: transient deleterious effects and enhanced motivation in both intact and parkinsonian rats. Eur J Neurosci (2007) 0.85
Disrupting neuronal transmission: mechanism of DBS? Front Syst Neurosci (2014) 0.84
Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's disease. Behav Brain Funct (2015) 0.84
Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat (2011) 0.83
Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 0.82
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys. Mov Disord (2008) 0.80
Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption? Neuroscientist (2015) 0.79
Surgical insights into Parkinson's disease. J R Soc Med (2006) 0.78
Pedunculopontine stimulation from primate to patient. J Neural Transm (Vienna) (2011) 0.77
Parkinson's Disease: Surgical Options. Curr Treat Options Neurol (2003) 0.76
Non-Human Primate: An Essential Building Brick in the Discovery of the Subthalamic Deep Brain Stimulation Therapy. Front Aging Neurosci (2016) 0.75
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: Why so successful? Surg Neurol Int (2012) 0.75
Improvement of Advanced Parkinson's Disease Manifestations with Deep Brain Stimulation of the Subthalamic Nucleus: A Single Institution Experience. Brain Sci (2016) 0.75
Deep brain stimulation in the central nucleus of the amygdala decreases 'wanting' and 'liking' of food rewards. Eur J Neurosci (2016) 0.75
Parkinson's disease and primate research: past, present, and future. Postgrad Med J (2006) 0.75
Alim-Louis Benabid and Mahlon DeLong win the 2014 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest (2014) 0.75
Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review. Parkinsons Dis (2017) 0.75
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology (2005) 1.75
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
Source localisation of 62-electrode human laser pain evoked potential data using a realistic head model. Int J Psychophysiol (2001) 1.39
Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (1997) 1.38
The clinical and surgical feature in 40 patients with primary cerebellar ectopia (adult Chiari malformation). Q J Med (1977) 1.37
Problems associated with iontophoretic studies in the caudate nucleus and substantia nigra. Neuropharmacology (1974) 1.37
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain (1984) 1.14
Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia (1993) 1.12
Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience (1987) 1.04
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol (2000) 1.00
Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine. J Pharm Pharmacol (1974) 0.99
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol (1998) 0.98
Myasthenia gravis: clinical and histological features in relation to thymectomy. J Neurol Neurosurg Psychiatry (1976) 0.96
Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience (1983) 0.96
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol (1999) 0.95
Cerebrospinal fluid absorption in primary hypoparathyroidism. J Neurol Neurosurg Psychiatry (1977) 0.95
Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings]. Br J Pharmacol (1977) 0.95
The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. Brain Res (1971) 0.93
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord (1991) 0.92
Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neurosci Lett (1984) 0.90
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord (2001) 0.90
Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat. Br J Pharmacol (1974) 0.89
Nucleus tegmenti pedunculopontinus: efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience (1983) 0.89
Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. Eur J Neurosci (1994) 0.88
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord (1999) 0.88
The effect of morphine on turning behaviour in rats and mice with unilateral 6-hydroxydopamine lesions [proceedings]. Br J Pharmacol (1976) 0.87
Basal ganglia and other afferent projections to the peribrachial region in the rat: a study using retrograde and anterograde transport of horseradish peroxidase. Neuroscience (1981) 0.87
Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology (1985) 0.87
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol (1994) 0.87
Induction of chorea and dystonia in parkinsonian primates. Mov Disord (1990) 0.86
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol (2001) 0.86
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res (1993) 0.86
The relationship between cerebrospinal fluid and plasma electrolytes in patients with meningitis. J Neurol Sci (1974) 0.86
Picrotoxin antagonism of gamma-aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra. Br J Pharmacol (1973) 0.86
Anatomic localization of dyskinesia in children with "profound" perinatal hypoxic-ischemic injury. AJNR Am J Neuroradiol (2009) 0.86
Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res (1989) 0.85
A method for investigating neurotransmission in the basal ganglia using combined stimulation and intracerebral drug injection [proceedings]. Br J Pharmacol (1977) 0.85
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J (2001) 0.85
The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain (1989) 0.85
Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg (1992) 0.85
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (1997) 0.85
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res (1990) 0.84
Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett (1985) 0.84
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res (1992) 0.84
Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neurosci Lett (1984) 0.84
Further evidence for the stimulation of rat brain dopamine receptors by ergometrine. J Pharm Pharmacol (1974) 0.84
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (2001) 0.84
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1989) 0.84
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett (1986) 0.84
A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett (1994) 0.83
Subthalamic nucleus efferent projection to the cerebral cortex. Neuroscience (1981) 0.83
[3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Mov Disord (1998) 0.83
Metabolic studies in subarachnoid haemorrhage and strokes. I. Serial changes in acid-base values in blood and cerebrospinal fluid. Brain (1973) 0.83
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci (1987) 0.82
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord (1990) 0.82
The efferent projections of the nucleus accumbens in the rat. Brain Res (1977) 0.82
Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat. Brain Res (1994) 0.82
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Exp Neurol (1996) 0.82
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol (1996) 0.82
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol (2001) 0.81
Metabolic studies in subarachnoid haemorrhage and strokes. II. Serial changes in cerebrospinal fluid and plasma urea electrolytes and osmolality. Brain (1973) 0.81
Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. Eur J Pharmacol (1987) 0.81
Experimental torticollis in the monkey produced by unilateral 6-hydroxy-dopamine brain lesions. Brain Res (1978) 0.81